CN105705518A - 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体 - Google Patents

用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体 Download PDF

Info

Publication number
CN105705518A
CN105705518A CN201480047403.XA CN201480047403A CN105705518A CN 105705518 A CN105705518 A CN 105705518A CN 201480047403 A CN201480047403 A CN 201480047403A CN 105705518 A CN105705518 A CN 105705518A
Authority
CN
China
Prior art keywords
dose
csf
functional fragment
primate
neutralizing antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480047403.XA
Other languages
English (en)
Chinese (zh)
Inventor
T.瓦格纳
M.卡尔森
M.斯陶姆卡尔托夫特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda GmbH filed Critical Takeda GmbH
Priority to CN202410511905.9A priority Critical patent/CN118178647A/zh
Publication of CN105705518A publication Critical patent/CN105705518A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480047403.XA 2013-08-30 2014-09-01 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体 Pending CN105705518A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410511905.9A CN118178647A (zh) 2013-08-30 2014-09-01 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361871900P 2013-08-30 2013-08-30
US201361871904P 2013-08-30 2013-08-30
US61/871904 2013-08-30
US61/871900 2013-08-30
PCT/EP2014/068489 WO2015028657A1 (en) 2013-08-30 2014-09-01 Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410511905.9A Division CN118178647A (zh) 2013-08-30 2014-09-01 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体

Publications (1)

Publication Number Publication Date
CN105705518A true CN105705518A (zh) 2016-06-22

Family

ID=51454704

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480047403.XA Pending CN105705518A (zh) 2013-08-30 2014-09-01 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体
CN202410511905.9A Pending CN118178647A (zh) 2013-08-30 2014-09-01 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410511905.9A Pending CN118178647A (zh) 2013-08-30 2014-09-01 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体

Country Status (12)

Country Link
US (2) US10745475B2 (cg-RX-API-DMAC7.html)
EP (2) EP3889178A1 (cg-RX-API-DMAC7.html)
JP (4) JP2016536327A (cg-RX-API-DMAC7.html)
KR (3) KR20240090993A (cg-RX-API-DMAC7.html)
CN (2) CN105705518A (cg-RX-API-DMAC7.html)
AU (3) AU2014314053C1 (cg-RX-API-DMAC7.html)
BR (1) BR112016003293A8 (cg-RX-API-DMAC7.html)
CA (1) CA2922251C (cg-RX-API-DMAC7.html)
ES (1) ES2860480T3 (cg-RX-API-DMAC7.html)
MX (2) MX385854B (cg-RX-API-DMAC7.html)
RU (1) RU2714919C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015028657A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109219616A (zh) * 2016-09-19 2019-01-15 天境生物 Gm-csf抗体及其用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102210852B (zh) 2003-05-15 2016-10-19 安皮奥制药股份有限公司 T-细胞介导的疾病的治疗
PH12014500685B1 (en) 2011-10-10 2018-10-03 Ampio Pharmaceuticals Inc Treatment of degenerative joint disease
EP4066836A1 (en) 2014-08-18 2022-10-05 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW-MOLECULAR FRACTIONS OF HUMAN SERUMALBUMINE IN THE TREATMENT OF ILLNESSES
CN107840885B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
JP7630906B2 (ja) 2017-02-01 2025-02-18 イェール・ユニヴァーシティー 利尿薬耐性の治療
SG11202006157VA (en) * 2018-01-05 2020-07-29 Corvidia Therapeutics Inc Methods for treating il-6 mediated inflammation without immunosuppression
SG11202008934PA (en) * 2018-03-14 2020-10-29 Univ Indiana Res & Tech Corp Precision medicine for pain: diagnostic biomarkers, pharmacogenomics, and repurposed drugs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101184777A (zh) * 2005-04-18 2008-05-21 米克罗麦特股份公司 人粒细胞巨噬细胞集落刺激因子的抗体中和剂

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
JPS59147297A (ja) 1983-02-10 1984-08-23 株式会社日立製作所 原子炉圧力容器の耐震構造
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0158487B1 (en) 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
GB8624899D0 (en) 1986-10-17 1986-11-19 Sandoz Ltd Monoclonal antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5070013A (en) 1988-05-31 1991-12-03 Schering Corporation Immunochemical assay for human granulocyte-macrophage colony stimulating factor
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
CA2060741A1 (en) 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
WO2001058459A1 (fr) 2000-02-14 2001-08-16 Mitsubishi Pharma Corporation Remedes contre l'hepatite c
US20050271663A1 (en) 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US20030138417A1 (en) 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
ATE444308T1 (de) 2002-02-13 2009-10-15 Ludwig Inst Cancer Res Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
CA2476934C (en) 2002-02-27 2009-06-16 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
NZ539271A (en) 2002-10-30 2008-12-24 Genentech Inc Inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23)
AU2005249360B2 (en) 2004-04-12 2011-07-21 Medimmune, Llc Anti-IL-9 antibody formulations and uses thereof
ATE435238T1 (de) 2004-05-05 2009-07-15 Micromet Ag Herstellung eines einkettigen fv antikörperfragments
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1828250A2 (en) 2004-12-16 2007-09-05 Genentech, Inc. Methods for treating autoimmune disorders
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
ES2918209T3 (es) 2005-05-18 2022-07-14 Morphosys Ag Anticuerpos anti-GM-CSF y usos a partir de los mismos
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトgm−csfに結合するヒトのモノクローナル抗体並びにその抗原結合部分
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン,エルエルシー タンパク質製剤
KR101395515B1 (ko) 2006-02-08 2014-05-14 모르포테크, 인크. 항원성 gm-csf 펩티드 및 gm-csf에 대한 항체
KR101481844B1 (ko) 2006-03-27 2015-01-13 메디뮨 리미티드 Gm-csf 수용체에 대한 결합 성분
US20080206241A1 (en) * 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
AU2008269086B2 (en) 2007-06-25 2014-06-12 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US8679502B2 (en) 2007-11-13 2014-03-25 Evec Inc. Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same
KR101824512B1 (ko) 2008-04-28 2018-02-02 휴머니건, 아이엔씨. 과립구-대식세포 콜로니 자극 인자에 대한 항체
CA2717987C (en) 2008-04-29 2018-11-13 Micromet Ag Inhibitors of gm-csf and il-17 for therapy
EP3381471B1 (en) 2008-12-22 2024-03-20 The University of Melbourne Pain treatment
US20120116059A1 (en) 2009-05-05 2012-05-10 Morphosys Ag Treatment For M Treatment For Multiple Sclerosis
WO2011017070A1 (en) 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US20110158987A1 (en) 2009-12-29 2011-06-30 F. Hoffmann-Laroche Ag Novel antibody formulation
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
CN103906767A (zh) * 2011-10-10 2014-07-02 米迪缪尼有限公司 对类风湿关节炎的治疗
CN104995210A (zh) * 2012-09-20 2015-10-21 莫弗系统股份公司 类风湿关节炎的治疗
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2018025798A1 (ja) 2016-08-03 2018-02-08 古河電気工業株式会社 金属粒子含有組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101184777A (zh) * 2005-04-18 2008-05-21 米克罗麦特股份公司 人粒细胞巨噬细胞集落刺激因子的抗体中和剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BEHRENS FRANK等: "First in patient study of anti-GM-CSF monoclonal antibody(MOR103) in active rheumatoid arthritis: results of a phase 1b/2a randomized, double-blind, placebo-controlled trial", 《ARTHRITIS & RHEUMATISM》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109219616A (zh) * 2016-09-19 2019-01-15 天境生物 Gm-csf抗体及其用途
CN109219616B (zh) * 2016-09-19 2022-10-21 天境生物科技(杭州)有限公司 Gm-csf抗体及其用途

Also Published As

Publication number Publication date
JP2020109108A (ja) 2020-07-16
JP2022105160A (ja) 2022-07-12
MX2016002177A (es) 2016-06-28
RU2016109944A3 (cg-RX-API-DMAC7.html) 2018-07-09
JP2016536327A (ja) 2016-11-24
US20210171620A1 (en) 2021-06-10
AU2014314053C1 (en) 2023-11-02
BR112016003293A2 (pt) 2017-11-21
CA2922251A1 (en) 2015-03-05
KR20240090993A (ko) 2024-06-21
WO2015028657A1 (en) 2015-03-05
US20160355584A1 (en) 2016-12-08
MX385854B (es) 2025-03-18
US10745475B2 (en) 2020-08-18
EP3039039B1 (en) 2021-03-10
US11795216B2 (en) 2023-10-24
RU2714919C2 (ru) 2020-02-21
AU2020203917A1 (en) 2020-07-02
ES2860480T3 (es) 2021-10-05
EP3889178A1 (en) 2021-10-06
EP3039039A1 (en) 2016-07-06
MX2021010472A (es) 2021-10-01
KR20160044035A (ko) 2016-04-22
AU2023210647A1 (en) 2023-10-12
KR20220045064A (ko) 2022-04-12
CN118178647A (zh) 2024-06-14
BR112016003293A8 (pt) 2022-08-16
CA2922251C (en) 2023-10-17
AU2014314053B2 (en) 2020-03-12
AU2014314053A1 (en) 2016-02-11
JP2024123249A (ja) 2024-09-10
RU2016109944A (ru) 2017-10-06

Similar Documents

Publication Publication Date Title
US11795216B2 (en) Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
AU2011325134B2 (en) Methods of treating rheumatoid arthritis using IL-17 antagonists
JP2021193121A (ja) Il−17アンタゴニストを使用して汎発性膿疱性乾癬(gpp)を処置する方法
AU2015313827C1 (en) Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
JP2022126791A (ja) Il-17アンタゴニストを用いて初発プラーク型乾癬を治療する方法
AU2024202601A1 (en) Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
TW202539734A (zh) 使用白細胞介素-17(il-17)拮抗劑治療自體免疫性疾病之方法
CN112512578A (zh) 结合cd123和cd3的双特异性抗体的给药
TWI737000B (zh) 用於治療化膿性汗腺炎之泛-elr+cxc趨化介素抗體
CN119546340A (zh) 使用白细胞介素-17(il-17)拮抗剂选择性治疗肌腱病的方法
HK40062612A (en) Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
HK40110169A (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
WO2015028666A1 (en) Neutralizing antibody or a fragment thereof specifically binding primate gm-csf for use in the treatment and/or prevention of psoriasis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220216

Address after: Osaka City, Osaka of Japan

Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Konstanz

Applicant before: TAKEDA GmbH

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160622